Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cefazolin prophylaxis for prevention of wound infection after lower-extremity implant removal
NL-OMON44330Phase 4Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2014
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in surgical site infection (SSI) comparing Cefazolin prophylaxis with Placebo saline control (2 arms). Primary endpoint: Incidence of wound infection within 30 days. Started Nov 2014; status: active, not recruiting.
02
Drugs
cefazolin
03
Conditions
surgical site infection (SSI)
Beyond the preview
Go deeper on NL-OMON44330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44330.